New York, United States, Aug. 02, 2023 (GLOBE NEWSWIRE) -- An oral thin film (OTF) is a very thin film composed of a mono or multi-layer polymeric matrix applied in the mouth. OTFs are commonly soluble, water-based polymers designed for rapid drug administration. The oral route is the most advised method for delivering therapeutic drugs due to its simplicity, low cost of therapy, and high patient compliance rate. Tablets and capsules are the two oral solid dose forms most frequently used. Patients who are bedridden, old, or young patients, however, have trouble swallowing regular oral dosage forms. After successfully overcoming this obstacle, oral rapid-dissolving films, referred to as oral thin films (OTFs), have gained broad attention.
Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/oral-thin-films-market/request-sample
Growing Burden of Target Diseases Drives the Global Market
Patients with specific conditions, such as Migraine, schizophrenia, Parkinson's disease, Alzheimer's disease, and others, are given oral thin films to make them feel better. The market for oral thin films is expected to grow over the projected period since older people can take prescriptions less easily. Migraine, a common neurological disorder, is one of the most common medical conditions in the world.
According to the American Migraine Foundation, migraines are the third most common ailment, affecting one in seven people globally. It affects about 37 million Americans. The disease will affect 148 million people worldwide in the upcoming years. As a result, it is projected that as migraine incidence rises, there will be an increase in demand for oral medicine delivery modalities. Due to enhanced absorption and an earlier beginning of the action, Zolmitriptan sublingual film has been demonstrated to be a better option for treating acute migraine attacks than standard dosages.
Growing Demand for Sublingual Film Creates Tremendous Opportunities
Thin films are studied by pharmaceutical experts worldwide as a cutting-edge medication delivery technique. It has been noticed that thin films can be used as an alternative to conventional dose forms. The sublingual route is utilized to administer drugs with high mucosal permeability and is intended to treat acute disorders. The active components are administered systemically via diffusing through the tongue's ventral surface and the floor of the mouth. Additionally, sublingual films with characteristics including dissolution rates, adhesion, film thickness, material composition, taste-masking, and active medicinal ingredient absorption rates are available on the market. Dissolution may begin in reaction to a specific biological fluid, pH, or other situation. Products with many layers could be made for optimum bioavailability and stability.
Report Scope
Report Metric | Details |
Market Size by 2031 | USD 5,357.18 million |
Market Size in 2022 | USD 2,577.18 million |
CAGR | 8.47% |
Historical Data | 2020-2021 |
Base Year | 2022 |
Forecast Period | 2023-2031 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Product, Disease Indication, Distribution Channel |
Geographies Covered | North America, Europe, Asia-Pacific, LAME and Rest of the World |
Key Companies Profiled/Vendors | Aquestive Therapeutics Inc., IntelGenx Corp., LTS Lohmann Therapie-Systeme AG, Viatris, NAL Pharma, ZIM Laboratories Limited, Sunovion Pharmaceuticals Inc., Cure Pharmaceutical, and C.L.Pharm. |
Key Market Opportunities | Growing Demand for Sublingual Film |
Key Market Drivers | Growing Burden of Target Diseases |
Buy Now Full Report @ https://straitsresearch.com/buy-now/oral-thin-films-market
Regional Analysis
North America is the most significant revenue contributor and is expected to grow at a CAGR of 8.13% during the forecast period. The United States has the largest market share in North America since a significant portion of the population is considering schizophrenia drug therapy due to their hectic lifestyles. The National Alliance on Mental Illness estimates that every year in the United States, 1.5 million adults will develop schizophrenia. Schizophrenia symptoms appear earlier in males than women, typically diagnosed in young individuals between late adolescence and early adulthood. Throughout the projected period, market growth is anticipated to be fueled by the launch of new products and the presence of prominent industry players. Due to factors such as the rising prevalence of specific ailments, the advantages of oral thin films like rapid absorption, and collaboration among market participants, the industry is growing. The prospect of rising drug and addiction rates may also help Mexico's market expansion despite the confluence of local and global factors. Market participants' strategic steps to advertise their presence in the Mexican market aid the industry's expansion.
Europe is expected to grow at a CAGR of 8.93% during the forecast period. The market for oral thin films in Germany is projected to expand quickly due to the country's sophisticated healthcare system and developing nanotechnology-based pharmaceutical sector. Several market players also fuel the expansion of the domestic market. For instance, Vektor Pharma TF GmbH and its personnel have innovated in designing, testing, and producing thin-film pharmaceutical formulations. The market's expansion is also aided by the strategic agreement reached by market participants to improve their national positions. It is projected that factors such as the rising incidence of mental illnesses, the volume of research and development initiatives, and the launch of new products with cutting-edge technology will boost the market for oral thin films in the United Kingdom. Apomorphine sublingual film treats OFF episodes in Parkinson's patients, and Sunovion Pharmaceuticals Inc. agreed to give BIAL exclusive commercial license rights in Europe. Product distribution throughout the European Union (EU), the European Economic Area (EEA), and the United Kingdom are mandated under this agreement for BIAL. The market may benefit as a result of this.
Key Highlights
- The global oral thin films market size is projected to reach USD 5,357.18 million by 2031, growing at a CAGR of 8.47% during the forecast period (2023-2031).
- Based on product, the global oral thin film market is bifurcated into sublingual, fast dissolving dental/buccal film. The sublingual film segment is the highest contributor to the market and is estimated to grow at a CAGR of 8.26% during the forecast period.
- Based on disease indication, the global oral thin films market is bifurcated into schizophrenia, Migraine, opioid dependence, nausea and vomiting, and other disease indications. The opioid dependence segment is the highest contributor to the market and is estimated to grow at a CAGR of 8.71% during the forecast period.
- Based on distribution channels, the global oral thin films market is bifurcated into hospital pharmacies, retail pharmacies, and other distribution channels. The retail pharmacies segment is the highest contributor to the market and is estimated to grow at a CAGR of 8.59% during the forecast period.
- North America is the most significant revenue contributor and is expected to grow at a CAGR of 8.13% during the forecast period.
Competitors in Oral Thin Films Market
- Aquestive Therapeutics Inc.
- IntelGenx Corp.
- LTS Lohmann Therapie-Systeme AG
- Viatris
- NAL Pharma
- ZIM Laboratories Limited
- Sunovion Pharmaceuticals Inc
- Cure Pharmaceutical
- C.L.Pharm
Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/oral-thin-films-market/request-sample
Segmentation of Oral Thin Films Market
By Product
- Sublingual Film
- Fast Dissolving Dental/Buccal Film
By Disease Indication
- Schizophrenia
- Migraine
- Opioid Dependence
- Nausea and Vomiting
- Other Disease Indication
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Other Distribution Channels
By Regions
- North America
- Europe
- Asia-Pacific
- LAMEA
Table Of Content
- Executive Summary
- Research Scope & Segmentation
- Research Objectives
- Market Definition
- Limitations & Assumptions
- Market Scope & Segmentation
- Currency & Pricing Considered
- Market Opportunity Assessment
- Emerging Regions / Countries
- Emerging Companies
- Emerging Applications / End Use
- Investment Landscape
- New Business Models / Revenue Streams
- TAM
- Market Trends
- Drivers
- Market Warning Factors
- Latest Macro Economic Indicators
- Geopolitical Impact
- Human Factors
- Technology Factors
- Market Assessment
- Porters Five Forces Analysis
- Value Chain Analysis
- Sales And Distribution Channel Analysis
- Case Study Analysis
- Patent Analysis
- M & A Agreements & Collabration Analysis
- ESG Trends
- Global Oral Thin Films Market Size Analysis
- Global Oral Thin Films Market Introduction
- By Product
- Introduction
- Product By Value
- Sublingual Film
- By Value
- Fast Dissolving Dental/Buccal Film
- By Value
- Introduction
- By Disease Indication
- Introduction
- Disease Indication By Value
- Schizophrenia
- By Value
- Migraine
- By Value
- Opioid Dependence
- By Value
- Nausea and Vomiting
- By Value
- Other Disease Indication
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospital Pharmacies
- By Value
- Retail Pharmacies
- By Value
- Other Distribution Channels
- By Value
- Introduction
- North America Market Analysis
- Introduction
- By Product
- Introduction
- Product By Value
- Sublingual Film
- By Value
- Fast Dissolving Dental/Buccal Film
- By Value
- Introduction
- By Disease Indication
- Introduction
- Disease Indication By Value
- Schizophrenia
- By Value
- Migraine
- By Value
- Opioid Dependence
- By Value
- Nausea and Vomiting
- By Value
- Other Disease Indication
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospital Pharmacies
- By Value
- Retail Pharmacies
- By Value
- Other Distribution Channels
- By Value
- Introduction
- U.S.
- By Product
- Introduction
- Product By Value
- Sublingual Film
- By Value
- Fast Dissolving Dental/Buccal Film
- By Value
- Introduction
- By Disease Indication
- Introduction
- Disease Indication By Value
- Schizophrenia
- By Value
- Migraine
- By Value
- Opioid Dependence
- By Value
- Nausea and Vomiting
- By Value
- Other Disease Indication
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospital Pharmacies
- By Value
- Retail Pharmacies
- By Value
- Other Distribution Channels
- By Value
- Introduction
- By Product
- Canada
- Europe Market Analysis
- Introduction
- By Product
- Introduction
- Product By Value
- Sublingual Film
- By Value
- Fast Dissolving Dental/Buccal Film
- By Value
- Introduction
- By Disease Indication
- Introduction
- Disease Indication By Value
- Schizophrenia
- By Value
- Migraine
- By Value
- Opioid Dependence
- By Value
- Nausea and Vomiting
- By Value
- Other Disease Indication
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospital Pharmacies
- By Value
- Retail Pharmacies
- By Value
- Other Distribution Channels
- By Value
- Introduction
- U.K.
- By Product
- Introduction
- Product By Value
- Sublingual Film
- By Value
- Fast Dissolving Dental/Buccal Film
- By Value
- Introduction
- By Disease Indication
- Introduction
- Disease Indication By Value
- Schizophrenia
- By Value
- Migraine
- By Value
- Opioid Dependence
- By Value
- Nausea and Vomiting
- By Value
- Other Disease Indication
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospital Pharmacies
- By Value
- Retail Pharmacies
- By Value
- Other Distribution Channels
- By Value
- Introduction
- By Product
- Germany
- France
- Spain
- Italy
- Russia
- Nordic
- Benelux
- Rest of Europe
- APAC Market Analysis
- Introduction
- By Product
- Introduction
- Product By Value
- Sublingual Film
- By Value
- Fast Dissolving Dental/Buccal Film
- By Value
- Introduction
- By Disease Indication
- Introduction
- Disease Indication By Value
- Schizophrenia
- By Value
- Migraine
- By Value
- Opioid Dependence
- By Value
- Nausea and Vomiting
- By Value
- Other Disease Indication
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospital Pharmacies
- By Value
- Retail Pharmacies
- By Value
- Other Distribution Channels
- By Value
- Introduction
- China
- By Product
- Introduction
- Product By Value
- Sublingual Film
- By Value
- Fast Dissolving Dental/Buccal Film
- By Value
- Introduction
- By Disease Indication
- Introduction
- Disease Indication By Value
- Schizophrenia
- By Value
- Migraine
- By Value
- Opioid Dependence
- By Value
- Nausea and Vomiting
- By Value
- Other Disease Indication
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospital Pharmacies
- By Value
- Retail Pharmacies
- By Value
- Other Distribution Channels
- By Value
- Introduction
- By Product
- Korea
- Japan
- India
- Australia
- Taiwan
- South East Asia
- Rest of Asia-Pacific
- Middle East and Africa Market Analysis
- Introduction
- By Product
- Introduction
- Product By Value
- Sublingual Film
- By Value
- Fast Dissolving Dental/Buccal Film
- By Value
- Introduction
- By Disease Indication
- Introduction
- Disease Indication By Value
- Schizophrenia
- By Value
- Migraine
- By Value
- Opioid Dependence
- By Value
- Nausea and Vomiting
- By Value
- Other Disease Indication
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospital Pharmacies
- By Value
- Retail Pharmacies
- By Value
- Other Distribution Channels
- By Value
- Introduction
- UAE
- By Product
- Introduction
- Product By Value
- Sublingual Film
- By Value
- Fast Dissolving Dental/Buccal Film
- By Value
- Introduction
- By Disease Indication
- Introduction
- Disease Indication By Value
- Schizophrenia
- By Value
- Migraine
- By Value
- Opioid Dependence
- By Value
- Nausea and Vomiting
- By Value
- Other Disease Indication
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospital Pharmacies
- By Value
- Retail Pharmacies
- By Value
- Other Distribution Channels
- By Value
- Introduction
- By Product
- Turkey
- Saudi Arabia
- South Africa
- Egypt
- Nigeria
- Rest of MEA
- LATAM Market Analysis
- Introduction
- By Product
- Introduction
- Product By Value
- Sublingual Film
- By Value
- Fast Dissolving Dental/Buccal Film
- By Value
- Introduction
- By Disease Indication
- Introduction
- Disease Indication By Value
- Schizophrenia
- By Value
- Migraine
- By Value
- Opioid Dependence
- By Value
- Nausea and Vomiting
- By Value
- Other Disease Indication
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospital Pharmacies
- By Value
- Retail Pharmacies
- By Value
- Other Distribution Channels
- By Value
- Introduction
- Brazil
- By Product
- Introduction
- Product By Value
- Sublingual Film
- By Value
- Fast Dissolving Dental/Buccal Film
- By Value
- Introduction
- By Disease Indication
- Introduction
- Disease Indication By Value
- Schizophrenia
- By Value
- Migraine
- By Value
- Opioid Dependence
- By Value
- Nausea and Vomiting
- By Value
- Other Disease Indication
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospital Pharmacies
- By Value
- Retail Pharmacies
- By Value
- Other Distribution Channels
- By Value
- Introduction
- By Product
- Mexico
- Argentina
- Chile
- Colombia
- Rest of LATAM
- Competitive Assessment
- Adoption Matrix
- Oral Thin Films Market Share By Manufacturers
- Oral Thin Films Market Ranking By Revenue For Manufacturers
- Average Price By Manufacturers
- Vendor Footprint Analysis
- Market Players Assessment
- Aquestive Therapeutics Inc.
- Overview
- Business Information
- Revenue
- ASP
- Gross Margin
- Swot Analysis
- Recent Developmments
- IntelGenx Corp.
- LTS Lohmann Therapie-Systeme AG
- Viatris, NAL Pharma
- ZIM Laboratories Limited
- Sunovion Pharmaceuticals Inc.
- Cure Pharmaceutical
- C.L.Pharm
- Aquestive Therapeutics Inc.
- Research Methodology
- Research Data
- Secondary Data
- Major secondary sources
- Key data from secondary sources
- Primary Data
- Key data from primary sources
- Breakdown of primaries
- Secondary And Primary Research
- Key industry insights
- Secondary Data
- Market Size Estimation
- Bottom-Up Approach
- Top-Down Approach
- Market Projection
- Research Assumptions
- Assumptions
- Limitations
- Risk Assessment
- Research Data
- Appendix
- Discussion Guide
- Customization Options
- Related Reports
- Disclaimer
Table of Content and Figure @ https://straitsresearch.com/report/oral-thin-films-market/toc
Recent Development
- In October 2022, Aquestive Therapeutics licensed Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.
- In October 2022, IntelGenx Corp. (the "Company" or "IntelGenx") provided an update on its collaboration with its strategic partner, Life Sciences, for the development of novel formulations of pharmaceutical-grade psychedelics based on IntelGenx's polymeric film technologies.
News Media
Global Flexible Thin Film and Printed Battery Market to Grow at a CAGR of 31% by 2030
Global Oral Thin Films Market Size USD 5,357.18 million by 2031 | CAGR of 8.47%
Have a Look at the Related Research Report
Flexible Thin Film and Printed Battery Market: Information by Chargeability (Rechargeable and Non-rechargeable), Application (Consumer Electronics), and Region- Forecast till 2030
Breathable Films Market: Information by Raw Material (Polyester, Polyethylene), Product (Microporous, Micro void), and Region — Forecast till 2030
Adhesive Film Market: Information by Film Material (Polypropylene, Polyvinyl Chloride, Polyethylene), Technology (Water-based, Solvent-based, Hot Melt), End-User Industry (Electrical and Electronics, Aerospace), and Region—Forecast Till 2031
Paint Protection Film Market: Information by Application (Automotive and Transportation, Electrical and Electronics, Aerospace and Defense), and Region — Forecast till 2030
Fluoropolymer Films Market: Information by Type (PTFE, PVDF, FEP) Applications (Barrier Films, Release Films) End-User Industry (Automotive, Aerospace and Defense) Regions—Forecast Till 2031
Solar Control Window Films Market: Information by Type (Dyed, Vacuum, Clear), Absorber Type (Organic, Inorganic, Metallic), Application (Construction, Automotive, Marine), and Regions—Forecast till 2031
Sustainable Films for Packaging Market: Information by Applications (Food and Beverage, Pharmaceutical) Materials (Polyethylene Terephthalate (PET)), and Regions—Forecast till 2031
Thermoplastic Polyurethane (TPU) Films Market: Information by Chemical Class (Polyester, Polyether), End-User Industry (Footwear, Sports Equipment), and Region — Forecast till 2031
About Straits Research Pvt. Ltd.
StraitsResearch is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.
Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.
For more information on your target market, please contact us below:
Phone: +1 646 480 7505 (the U.S.)
+91 8087085354 (APAC)
+44 208 068 9665 (the U.K.)
Email: sales@straitsresearch.com
Follow Us: LinkedIn | Facebook | Instagram | Twitter